Skip to content

Author

J. Väyrynen

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

The Tumor Microenvironment Score and Its Subsite-Specific Relevance in Colon Cancer.

Colon cancer is a major global malignancy with significant mortality. Right-sided (RCC) and left-sided colon cancers (LCC) exhibit distinct clinicopathological characteristics. Tumor microenvironment score (TMS) combines Klintrup-Mäkinen grade, tumor stroma percentage, and tumor budding, classifying cases into 4 groups (TMS 0-3). Evaluation of TMS is an integrative method for prognostic classification; however, further validation is needed, and differences between RCC and LCC remain unclear. A discovery cohort (n=940) and a validation cohort (n=613) were retrospectively included. TMS was evaluated from hematoxylin-eosin-stained slides. Five-year disease-specific survival (DSS) was analyzed using life-table methods and Cox regression. Associations with clinicopathological variables were assessed. In both the discovery and validation cohorts, higher TMS was associated with worse 5-year DSS in univariable analyses for both RCC and LCC. In multivariable analysis, high TMS (TMS3 vs. TMS0) remained independently associated with survival in the discovery cohort (RCC-HR: 2.47, 95% CI: 1.36-4.46, P=0.003; LCC-HR: 3.08, 95% CI: 1.46-6.45, P=0.003). In the validation cohort, the prognostic impact of TMS was more pronounced in RCC (HR: 4.35, 95% CI: 2.32-8.14, P<0.001) than in LCC (HR: 2.21, 95% CI: 0.81-6.03, P=0.12). TMS also appeared to provide improved prognostic stratification compared with the Glasgow microenvironment score (combination of Klintrup-Mäkinen grade and tumor stroma percentage). In conclusion, TMS serves as an integrative histopathological marker with potential to improve prognostic stratification in colon cancer, particularly in right-sided tumors.

Mari J. Jawad, Vilja V Tapiainen, Ville K. Äijälä et al. · 0 citations
Open access Aug 2026

Epithelial interferon-stimulated gene programs modulate chemotherapy sensitivity in colorectal cancer via EPSTI1.

Although chemotherapy in colorectal cancer (CRC) primarily targets epithelial tumor cells, the epithelial cell-intrinsic mechanisms underlying heterogeneous treatment responses remain poorly understood. We integrated the genomic, transcriptomic, and in vitro drug response profiles of CRC patient-derived tumor organoids (PDTOs) with functional assays to identify epithelial cell-intrinsic determinants of chemotherapy response. An epithelial interferon-stimulated gene (ISG) program, reflecting JAK-STAT pathway activity, was associated with reduced chemosensitivity in PDTOs. Single-cell RNA sequencing data of CRC tumors before and after neoadjuvant chemotherapy showed persistent epithelial ISG expression, with EPSTI1 notably enriched in tumors with incomplete pathological responses. Functional studies demonstrated that EPSTI1 knockdown reduced CRC cell viability and enhanced chemosensitivity. Pharmacologic JAK-STAT inhibition with ruxolitinib suppressed ISG expression and attenuated chemotherapy-induced ISG upregulation. These findings highlight the utility of PDTOs for studying tumor-intrinsic mechanisms of treatment response and identify EPSTI1 as an epithelial modulator of chemosensitivity.

E. Erkan, Emmi Hämäläinen, Julia Kolikova et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.